Quantum-Si (QSI) Expected to Announce Quarterly Earnings on Monday

Quantum-Si (NASDAQ:QSI) is expected to be announcing its earnings results after the market closes on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $1.23 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Quantum-Si Stock Up 2.2 %

NASDAQ QSI opened at $1.38 on Friday. Quantum-Si has a 52-week low of $0.61 and a 52-week high of $5.77. The business’s 50-day moving average price is $2.23 and its 200 day moving average price is $1.44. The firm has a market cap of $196.94 million, a P/E ratio of -2.16 and a beta of 2.70.

Wall Street Analysts Forecast Growth

QSI has been the topic of a number of analyst reports. Canaccord Genuity Group lowered their price objective on Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, November 13th. Alliance Global Partners initiated coverage on Quantum-Si in a report on Friday, February 7th. They issued a “buy” rating and a $3.75 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $5.50 price target on shares of Quantum-Si in a research note on Tuesday, January 14th.

Insider Buying and Selling

In other Quantum-Si news, Director Jonathan M. Rothberg sold 3,506,267 shares of the business’s stock in a transaction on Friday, December 27th. The stock was sold at an average price of $3.34, for a total value of $11,710,931.78. Following the completion of the transaction, the director now directly owns 1,250,000 shares in the company, valued at approximately $4,175,000. The trade was a 73.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 30.04% of the company’s stock.

Quantum-Si Company Profile

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.